Bruker Announces Agreement to Acquire Chemspeed
25 Janeiro 2024 - 9:00AM
Business Wire
Chemspeed Accelerates Bruker’s Laboratory
Automation and Digitalization Drive
Bruker Corporation (Nasdaq: BRKR) today announced a definitive
agreement for the acquisition of Chemspeed Technologies AG, a Swiss
provider of vendor-agnostic automated laboratory R&D and QC
workflow solutions. Chemspeed is focused on modular automation and
robotics solutions for chemical research, pharma drug formulation,
materials research for cleantech and consumer applications.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240125759758/en/
Chemspeed’s modular, compact FLEX
automation workstations enhance chemical and materials science
R&D and lab productivity and quality, as well as improve return
on R&D investment. (Photo: Business Wire)
The Chemspeed acquisition accelerates Bruker’s entry into lab
automation, digitalization and scientific software solutions.
Chemspeed offers modular automation to enhance productivity in
R&D and QC departments to achieve more in less time and without
additional staff. Chemspeed complements Bruker’s vendor-agnostic
platform SciY™ for software automation and digital transformation
of R&D labs in the life science, biopharma and cleantech
industries.
Strategically, Chemspeed’s automation solutions strengthens
Bruker’s Project Accelerate 2.0 initiative ‘Assays, Software and
Aftermarket’. The closing of the transaction is expected to occur
in the first half of 2024, subject to regulatory reviews. Financial
details of the transaction were not disclosed. In 2023, Chemspeed
generated revenues greater than $50 million, and Chemspeed was
profitable.
Specifically, Chemspeed offers a portfolio of flexible
automation modules, ranging from bench-top workstations to
integrated automated R&D workflows, which can transform R&D
productivity in industries such as pharmaceuticals, biotech,
chemicals, cleantech, materials, cosmetics and food. Chemspeed
automation is used every day in top R&D and QC laboratories
globally, setting standards in lab automation. Chemspeed also
offers compliance-ready workflow solutions to automate and
digitalize R&D and QC in regulated environments, ensuring data
integrity, traceability and quality.
Dr. Rolf Gueller, the founder and CEO of Chemspeed, said: “Our
team is excited to join Bruker to further boost automated and
digitalized workflows for our customers. With decades of experience
in automating R&D workflows, our modular solutions accelerate
developments, allowing lab technicians and scientists to focus on
their core competencies and creativity.” Going forward, Dr. Gueller
is expected to contribute to Chemspeed customers’ success on the
Chemspeed Advisory Board.
Dr. Falko Busse, the President of the Bruker BioSpin Group,
commented: “Chemspeed’s scalable modularity and flexibility
demonstrate what is achievable today in lab automation to customize
workflows, integrate automation layers with efficient workflow and
data management. We are excited to welcome the experienced team of
Chemspeed to Bruker. Their commitment to excellence is reflected in
the wide range of Chemspeed automation, and their dedication to
customer service.”
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high performance scientific instruments and high
value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular and cell biology research, in applied and pharma
applications, in microscopy and nanoanalysis, as well as in
industrial applications. Bruker offers differentiated, high-value
life science and diagnostics systems and solutions in preclinical
imaging, clinical phenomics research, proteomics and multiomics,
spatial and single-cell biology, functional structural and
condensate biology, as well as in clinical microbiology and
molecular diagnostics. For more information, please visit:
www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240125759758/en/
Investor: Justin Ward Sr. Director, Investor Relations
& Corporate Development Bruker Corporation T: +1 (978) 313-5800
E: Investor.Relations@bruker.com
Media: Markus Ziegler Sr. Director and Head of Group
Marketing Bruker BioSpin T: +49 172 3733531 E: pr@bruker.com
Bruker (NASDAQ:BRKR)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Bruker (NASDAQ:BRKR)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024